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Cystic	fibrosis	(CF)	is	caused	by	dysfunction	of	the	CF	transmembrane	conductance	regulator	(CFTR),	an	
anion	channel	whose	dysfunction	leads	to	chronic	bacterial	and	fungal	airway	infections	via	a	pathophysi-
ological	cascade	that	is	incompletely	understood.	Airway	glands,	which	produce	most	airway	mucus,	do	so	in	
response	to	both	acetylcholine	(ACh)	and	vasoactive	intestinal	peptide	(VIP).	CF	glands	fail	to	secrete	mucus	
in	response	to	VIP,	but	do	so	in	response	to	ACh.	Because	vagal	cholinergic	pathways	still	elicit	strong	gland	
mucus	secretion	in	CF	subjects,	it	is	unclear	whether	VIP-stimulated,	CFTR-dependent	gland	secretion	partici-
pates	in	innate	defense.	It	was	recently	hypothesized	that	airway	intrinsic	neurons,	which	express	abundant	
VIP	and	ACh,	are	normally	active	and	stimulate	low-level	gland	mucus	secretion	that	is	a	component	of	innate	
mucosal	defenses.	Here	we	show	that	low	levels	of	VIP	and	ACh	produced	significant	mucus	secretion	in	
human	glands	via	strong	synergistic	interactions;	synergy	was	lost	in	glands	of	CF	patients.	VIP/ACh	synergy	
also	existed	in	pig	glands,	where	it	was	CFTR	dependent,	mediated	by	both	Cl–	and	HCO3–,	and	clotrimazole	
sensitive.	Loss	of	“housekeeping”	gland	mucus	secretion	in	CF,	in	combination	with	demonstrated	defects	in	
surface	epithelia,	may	play	a	role	in	the	vulnerability	of	CF	airways	to	bacterial	infections.
Introduction
The recessive genetic disease cystic fibrosis (CF) is caused by the 
dysfunction of CF transmembrane conductance regulator (CFTR), 
an anion channel that is activated by pathways that elevate cAMP. 
In some epithelia, such as intestine (1, 2), pancreatic ducts (3, 4), 
and airway submucosal glands (5), CFTR mediates Cl–- or HCO3–-
dependent fluid secretion, and the loss of CFTR causes reduced 
fluid secretion in those organs. The most serious clinical problem 
in CF is lung damage caused by chronic bacterial airway infections. 
The bacteria in CF airways reside in the mucus, which in normal 
airways is sterile and mobile (6), suggesting that CF mucus is abnor-
mal both in its ability to be cleared from the airways (7) and in its 
antimicrobial properties (8). Most airway mucus is thought to arise 
from submucosal glands (9, 10), and in the only direct comparisons 
ever made of airways with and without glands, airways with glands 
secreted much more lysozyme and were more resistant to bacterial 
infections, even though no central innervation of the glands was 
present (11, 12). We hypothesize that abnormalities in airway gland 
mucus, secondary to loss of CFTR-mediated anion secretion, is a 
significant contributor to airways pathology in CF (13).
In humans and pigs, airway submucosal glands secrete mucus 
in response to both acetylcholine (ACh) and vasoactive intesti-
nal peptide (VIP) (5, 14). CF glands no longer secrete mucus in 
response to VIP (5), but do respond to carbachol (15). The nonhy-
drolyzable ACh analog carbachol produces maximal mucus secre-
tion rates (to 10 μM) that are about 2- to 3-fold greater than those 
caused by maximal VIP, and most studies of glands use maximal 
levels of cholinergic stimulation (10, 14). However, such stimuli 
are probably rarely experienced except in acute crises. Instead, 
mundane pathogens and irritants encountered continuously 
during normal breathing are more likely to produce low levels of 
stimulation via both neural and non-neural pathways. The com-
plex innervation of airway glands includes neurons intrinsic to 
the airways and employs multiple neurotransmitters, sometimes 
localized in the same neurons (16–21). These facts, in addition 
to the ability of centrally denervated airways in lung transplant 
patients to resist chronic infections and the presence of CFTR-
dependent local pathways in mouse airways (22), have led to a 
renewed interest in the local neural control of airway glands (23) 
and argue that the consequences of low-level stimulation by mixed 
agonists, which probably more closely approximate physiological 
conditions, need to be evaluated, particularly with reference to 
gland function in CF (see Discussion).
To our knowledge, the consequences of combinations of low-
level agonists on secretion of airway gland mucus have not pre-
viously been studied. The concentration of agonists that glands 
experience during normal breathing is not known, but airway 
vagal efferents display tonic activity during breathing (24), sug-
gesting a resting level of neural excitation of glands. Therefore, 
in order to determine whether any interactions exist among low 
levels of agonists, here we used optical methods to measure mucus 
secretion rates from single glands in situ (25) in response to VIP 
and carbachol, especially at nanomolar concentrations that might 
be expected to mimic routine physiological input to the glands. 
We demonstrated strong synergistic interactions between cho-
linergic and noncholinergic pathways in humans; importantly, 
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we found that those interactions were lost in human CF glands. 
We also demonstrated and analyzed VIP-carbachol synergy in pig 
submucosal glands. Some of these results have been reported in 
preliminary form in abstracts (26–28).
Results
Dose-response relations for single gland mucus secretion in human and pig 
airway glands. To begin the analysis of interactions between low 
levels of agonists, we first established dose-response relations for 
carbachol and VIP in non-CF human bronchi and tracheae and 
in pig tracheae, using optical methods to determine the rate of 
mucus secretion from single glands. As shown in Figure 1, pigs 
and humans had very similar dose-response relations for both 
agonists. For pigs the threshold (defined as the concentration 
which produced an obvious increase in mucus secretion rates for 
at least 2 glands in the optical field) for carbachol stimulation 
of gland mucus secretion was approximately 100 nM, the EC50 
was 590 ± 16 nM, and the approximate Vmax achieved with 10 μM 
carbachol was 3.43 ± 0. 29 nl/min/gland (n = 4, 27–43 glands; Fig-
ure 1A). For humans, the threshold for carbachol stimulation of 
gland secretion was approximately 50 nM, the EC50 was 545 ± 42 
nM, and the approximate Vmax was 3.51 ± 0.33 nl/min/gland 
(n = 3, 21 glands; Figure 1B). The threshold for VIP in pigs was 
approximately 20 nM, the EC50 was 834 ± 311 nM, and the extrap-
olated Vmax (not achieved with the maximal concentration of 10 
μM VIP) was 1.58 ± 0.18 nl/min/gland (n = 4, 25–36 glands; Figure 
1C). The threshold for VIP in humans was approximately 50 nM, 
the EC50 was 717 ± 76 nM, and maximal stimulation (probably 
less than Vmax and achieved with 10 μM VIP) was 1.54 ± 0.09 nl/
min/gland (n = 4, 24 glands; Figure 1D).
Human glands show synergistic secretory responses to VIP and carbachol. 
We used the dose-response relations to select concentrations for 
testing synergistic effects among VIP and carbachol. For human 
airway glands, subthreshold concentrations of VIP (10 nM) and 
carbachol (10 nM) produced significant mucus secretion when 
combined (Figure 2). Images of mucus bubbles under oil just 
before and 30 minutes after the combined stimulation are shown 
in Figure 2A. A plot of mucus volume versus time for 10 individual 
glands from a single subject is shown in Figure 2B, and summary 
data for 138 airway glands from 16 human subjects are shown in 
Figure 3. Essentially identical results were obtained for tracheal 
glands obtained from 9 donor tissues and from bronchial glands 
obtained from 7 controls with disease other than CF. Human 
glands secreted mucus in response to the combined stimuli at 
an average rate of 0.30 ± 0.18 nl/min/gland. This was a signifi-
cant increase (P < 0.001) over secretion in response to either agent 
alone and was approximately 20% of Vmax to VIP and 10% of Vmax 
to 10 μM carbachol. In terms of concentrations, the mucus secre-
tion produced by 10 nM VIP combined with 10 nM carbachol was 
approximately what would be expected with either 100 nM carba-
chol or 400 nM VIP alone. In 2 experiments with a single human 
subject with chronic obstructive pulmonary disease (disease 
control), 8 glands were followed for longer periods to determine 
whether there were delayed responses to 10 nM VIP or carbachol 
alone, and 13 glands were followed for 40–50 minutes with VIP 
and 1 hour with carbachol before applying the combined stimuli. 
No increase in mucus secretion was observed during these more 
prolonged periods, but rapid increases in secretion occurred to the 
combined stimuli for 10 of 13 glands (data not shown).
CF glands lack a synergistic secretory response to VIP and carbachol. 
Previous work showed that glands from subjects with CF are 
refractory to stimulation with VIP or forskolin, although they still 
respond to carbachol (5). To determine whether synergy between 
VIP and carbachol was also affected in subjects with CF, we applied 
Figure 1
Dose-response relations for 
airway gland mucus secretion. 
Shown are pig (A and C) and 
human (B and D) responses to 
carbachol (Carb; A and B) and 
VIP (C and D). Each point is the 
result of measurements of 21–43 
glands in 4 pigs or 3–4 humans. 
Vmax values were as follows (in nl/
min/gland): carbachol-exposed 
pig, 3.43 ± 0.29; carbachol-
exposed human, 3.55 ± 0.11; 
VIP-exposed pig, 1.58 ± 0.18; 
VIP-exposed human, 1.54 ± 0.09. 
EC50 values were as follows (in 
nM): carbachol-exposed pig, 
590 ± 16; carbachol-exposed 
human, 545 ± 42; VIP-exposed pig, 
834 ± 311; VIP-exposed human, 
717 ± 76.
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the same paradigm that produced synergy in human control tis-
sues to CF tissues. In marked contrast with controls, we found that 
CF glands failed to respond to the combination of carbachol and 
VIP that was efficacious in controls (Figure 2C and Figure 3). The 
mean response was essentially 0 (0.002 ± 0.008 nl/min; n = 7, 71 
glands) and did not differ significantly from the response to either 
agent alone. However, the CF glands were viable because they still 
responded vigorously to 1 μM carbachol, which produced mucus 
secretion of 3.10 ± 1.13 nl/min/gland (Figure 3, inset).
Synergistic stimulation of mucus secretion by VIP and carbachol in pig 
airway glands. Because pig airway tissues are consistently avail-
able, we sought to determine whether pig glands displayed a sim-
ilar form of synergy so that we could use pigs to begin analyzing 
the mechanisms of synergy. We found that pig tracheal glands, 
like human glands, showed marked synergy between subthresh-
old concentrations of VIP and carbachol (Figure 4). A single 
experiment recording 7 responding glands is shown in Figure 
4A, and the mean mucus secretion rate for each condition (n = 4, 
34 glands) is shown in Figure 4B. The response in the com-
bined condition was significantly increased versus either 
condition alone, producing a mean mucus secretion rate of 
0.33 ± 0.11 nl/min/gland (P < 0.01). Atropine (1 μM) had 
no effect on mucus secretion produced by suprathreshold 
levels of VIP used alone (data not shown), but, as expected, 
it abolished synergy between low levels of carbachol and VIP 
(n = 3, 19 glands; P < 0.05).
We next determined the interactions of VIP and carbachol 
over a range of agonist concentrations (n = 5, 9–36 glands, 
per condition). We first tested a 1,000-fold range of VIP con-
centrations (1 nM to 10 μM) either alone or with the addi-
tion of 20 or 50 nM carbachol, which are subthreshold when 
used alone in pigs. As shown in Figure 5A, either concentra-
tion of carbachol markedly increased mucus secretion for all 
VIP concentrations of 10 nM or greater. We then held the 
VIP concentration constant at 10 nM and added increasing 
concentrations of carbachol (1 nM to 10 μM). As shown in 
Figure 5B, synergy (and indeed additivity) was lost at carba-
chol concentrations greater than 100 nM, after which there 
was complete occlusion (n = 4, 7–45 glands, per condition). 
The dose response to carbachol alone was well fitted with a single 
sigmoid (P < 0.001), but the combination of VIP and carbachol 
was best fit with 2 sigmoids (the double sigmoid was better than 
a single sigmoid; P < 0.025), suggesting a second process was oper-
ating at lower concentrations.
Synergy dependent on cAMP and CFTR. To begin the analysis of the 
mechanisms responsible for synergy between carbachol and VIP, 
we first asked whether forskolin, which bypasses VIP receptors 
and directly activates adenylate cyclase, can substitute for VIP in 
the synergy paradigm. When combined with 20 nM carbachol, 100 
nM forskolin (a subthreshold concentration for pig and human 
gland mucus secretion when used alone; data not shown), pro-
duced in pigs a mucus secretion rate of 0.26 ± 0.08 nl/min/gland 
(Figure 4C), similar to the synergy produced by VIP (Figure 4B). 
Forskolin was also tested in experiments with 2 humans using 
100 nM forskolin alone or in combination with 10 nM carbachol. 
Of 10 glands tested, none responded to either agent alone, but 
8 of 10 glands secreted mucus in response to the combination 
Figure 2
Synergistic stimulation of human airway gland mucus secretion 
by carbachol in combination with VIP. (A) Raw data of the type 
used for analysis; 7 glands from a donor trachea supplied part of 
the data plotted in B. Each image shows the same airway region 
after being cleaned and oiled (see Methods). Mucus secretion 
from individual glands formed spherical bubbles in the oil, whose 
volume was measured optically. The top image was taken 40 min-
utes after sequential exposure to 10 nM carbachol and VIP (20 
minutes each) and the bottom image after 30 minutes exposure to 
the combined agonists. Arrows show corresponding gland open-
ings. Exposure to 20 nM of either agonist was ineffective (see 
Figure 1). Scale bar: 0.5 mm. (B) Plot of mucus volume versus 
time for 10 single glands stimulated sequentially with 10 nM car-
bachol, 10 nM VIP, and the combination. The tissue was washed 
for 1 minute with Krebs-Ringer buffer after carbachol. (C) Plot of 
10 bronchial glands from a single patient with CF stimulated with 
the identical protocol as the donor trachea. Unlike donor glands, 
no synergy occurred, but when the carbachol concentration was 
increased 100-fold to 1 μM, the CF glands secreted mucus vigor-
ously, indicating that they were still viable (not shown).
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(data not shown). Thus, forskolin could substitute for VIP to pro-
duce synergy with carbachol. This is of interest because a previous 
report of VIP-ACh synergy for glyconjugate release by cat glands 
found that db-cAMP could not substitute for VIP (29). This point 
is addressed again in Discussion.
Fluid secretion by pig airway glands is driven by anion secre-
tion (10, 30–34), and the lack of synergy in tissues from humans 
with CF indicated that synergy in humans requires CFTR. We 
next sought to determine the relative contributions of CFTR and 
Ca2+-activated chloride channels to the synergistic effect in pig 
glands. For this purpose, we stimulated mucus secretion with 20 
nM carbachol plus 10 nM VIP, which gave a mucus secretion rate 
of 0.29 ± 0.09 nl/min/gland, and then added either 40 μM niflu-
mic acid to inhibit Ca2+-activated chloride channels (35) or 20 μM 
CFTRinh-172 to inhibit CFTR channels (36) (Figure 6A). The syn-
ergistic response was not inhibited by 40 μM niflumic acid (mucus 
secretion rate, 0.27 ± 0.12 nl/min/gland; NS). In contrast, 20 μM 
CFTRinh-172 reduced the response significantly (mucus secretion 
rate, 0.08 ± 0.01 nl/min/gland; P < 0.01). Inhibition with CFTRinh-
172 was consistent with the lack of synergy in humans who lacked 
functional CFTR, as shown in Figure 2C and Figure 3. The lack 
of inhibition by niflumic acid could mean that Ca2+-activated 
chloride channels are not activated by low levels of carbachol, but 
before making this conclusion, we needed a positive control for 
the effects of niflumic acid on gland mucus secretion.
Role of Ca2+-activated Cl– channels. Mucus secretion by glands 
becomes at least partially independent of CFTR at higher con-
centrations of carbachol (refs. 5, 15, 22, 26, 37–40, and Figure 3, 
Figure 3
Summary data comparing synergistic stimulation of 
mucus secretion in human control glands with the lack of 
synergy in CF glands. Data was obtained from 9 donor 
tracheae (72 glands), bronchi from 7 disease controls 
(66 glands), and bronchi from 7 patients with CF (71 
glands). For each control group, the combined treat-
ments produced significantly greater mucus secretion 
than did either treatment alone, but CF subjects did not 
respond to the combined treatment, and the difference 
between CF and either control group was significant. 
**P < 0.01; ***P < 0.001. Inset: CF glands were still via-
ble, as determined by their robust secretion in response 
to a 100-fold higher concentration of carbachol.
Figure 4
Pig airway glands also show 
synergy between VIP and car-
bachol stimulation of mucus 
secretion. (A) An example of 
7 tracheal glands from a single 
pig trachea stimulated with 20 
nM carbachol, 10 nM VIP, and 
the combination. As in humans, 
synergy was observed with the 
combined treatment; a slightly 
higher carbachol concentra-
tion was used with pigs. (B) 
Summary data for 34 glands 
from 4 pigs. The response to 
combined agonists was sig-
nificantly greater than either 
agonist used alone. The syner-
gistic response was blocked by 
atropine (19 glands in 3 pigs). 
(C) Summary data for forskolin 
(Fors) and carbachol stimula-
tion of mucus secretion for 18 
glands from 3 pigs demonstrat-
ed that forskolin can substitute 
for VIP to produce synergy with 
carbachol. Note that 100 nM 
forskolin was required to see 
synergy equivalent to 10 nM 
VIP. *P < 0.05; **P < 0.01.
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inset), presumably because another apical Cl– channel is activated. 
Therefore, we stimulated tissues with a 5-fold greater concentra-
tion of carbachol (100 nM) in the absence of VIP — this level of 
carbachol produced a rate of mucus secretion similar to that pro-
duced by 20 nM carbachol plus 10 nM VIP (0.22 ± 0.02 nl/min/
gland) — and tested again with the same inhibitors (Figure 6B). 
Glands that secreted mucus in response to 100 nM carbachol 
alone here showed a different pattern of inhibition: niflumic acid 
and CFTRinh-172 each significantly inhibited the response by simi-
lar amounts. Inhibition by niflumic acid is consistent with activa-
tion of another anion channel, but inhibition by CFTRinh-172 was 
unexpected. This indicates that CFTR is partially active in these 
conditions, either because it has some level of basal activity or 
because it is being activated by this higher level of carbachol. The 
results to this point indicated that activation of CFTR is required 
for synergy and suggested that Ca2+-activated chloride channels 
are minimally involved, because niflumic acid had no detectable 
effect; the residual mucus secretion in the presence of CFTRinh-172 
may be explained by the incomplete inhibition of CFTR seen with 
this compound in some conditions (41, 42).
Role of Ca2+-activated K+ channels in synergy. Anion-driven fluid 
secretion by many epithelia is augmented by cell hyperpolariza-
tion, secondary to the activation of Ca2+-activated K+ channels 
(43). Thus, we considered the possibility that at the low levels of 
agonists used here, VIP activates only (or primarily) CFTR, and 
carbachol activates only (or primarily) Ca2+-activated K+ channels. 
To inhibit Ca2+-activated K+ channels, we applied clotrimazole (44) 
while stimulating glands with a just-suprathreshold concentration 
of VIP (100 nM) and a subthreshold concentration of carbachol 
(50 nM). These concentrations produced marked synergy (see Fig-
ure 5), but also provided a level of mucus secretion mediated by 
VIP alone against which the effects of clotrimazole could be tested. 
In different experiments, clotrimazole (25 μM) was applied either 
before or after the combination of VIP and carbachol. Clotrima-
zole abolished synergy whether added after (Figure 7A) or before 
Figure 5
Range of agonist concentrations over which synergy was observed in 
pig tracheal submucosal glands. (A) VIP varied from 1 nM to 10 μM 
with carbachol concentrations of 0, 20, and 50 nM. (B) Carbachol var-
ied from 1 nM to 10 μM alone and in the presence of 10 nM VIP.
Figure 6
Analysis of synergy in pig airway glands. (A) Synergy depended on 
CFTR and was not inhibited by niflumic acid (Nifl). The mean response 
to a 20-minute exposure to 20 nM carbachol plus 10 nM VIP was set to 
100%. For inhibitor studies, glands were pretreated with either niflumic 
acid or CFTRinh-172 for 1–5 minutes prior to exposure to the com-
bined agonists: CFTRinh-172, but not niflumic acid, significantly inhib-
ited the response. (B) Mucus secretion in response to suprathreshold 
carbachol displayed a different pharmacology. In these experiments 
the secretory response to a 20-minute exposure to 100 nM carbachol 
was set to 100%; this concentration was selected to produce a rate of 
mucus secretion similar to that observed with 20 nM carbachol plus 
10 nM VIP. To assess the inhibitors, the glands were pretreated as 
above with either niflumic acid or CFTRinh-172 followed by 100 nM 
carbachol. In contrast with the synergy condition, both niflumic acid 
and CFTRinh-172 significantly inhibited the response compared with 
carbachol alone, and the combination of inhibitors was additive. For 
each condition the number of subjects and number of glands (in paren-
theses) is shown. *P < 0.05; **P < 0.01.
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(Figure 7B) the VIP/carbachol combination while not affecting 
mucus secretion produced by VIP alone. Thus, at these low agonist 
concentrations, a clotrimazole-sensitive process is rate-limiting for 
mucus secretion in response to the combined agonists, but not for 
VIP alone. Figure 7, A and B, show results for individual glands 
from a single pig; summary data for clotrimazole are shown at the 
left of Figure 7D, which is based on 23 glands from 3 pigs.
As a further test of the hypothesis that synergy depends upon the 
separate recruitment of CFTR and Ca2+-activated K+ channels, we 
combined VIP with 1-ethyl-benzimidazolinone (1-EBIO), which is 
thought to directly activate Ca2+-activated, clotrimazole-sensitive 
K+ channels, as shown in the T-84 colonic crypt cell line (44), the 
Calu-3 airway gland serous cell line (45), and native intestinal tis-
sues of the mouse (46) and rat (44). We stimulated glands with 100 
nM VIP, 500 μM 1-EBIO, or the combination. In pig airway glands, 
1-EBIO alone did not stimulate mucus secretion, but when com-
bined with VIP it caused a 3-fold increase in secretion over that 
seen with VIP alone. Results for 10 glands in a single pig are shown 
in Figure 7C; summary data from 26 glands in 3 pigs is shown at 
the right of Figure 7D.
Mucus secretion relies on both Cl– and HCO3– transport. Prior work 
has shown that pig gland mucus secretion depends on both Cl– 
and HCO3– transport, and when one ion transport pathway is 
blocked the other can partially compensate (30–32, 47). In single 
gland studies using maximal stimulation (10 μM carbachol or 
10 μM forskolin), mucus secretion was inhibited 50%–60% either 
by bumetanide, which inhibits the Na+, K+, 2 Cl– cotransporter 
(NKCC), or by HCO3– replacement with HEPES, which was used 
to abrogate HCO3–-mediated fluid secretion. The combination of 
bumetanide and HCO3– replacement reduced mucus secretion by 
at least 90% (14). To determine whether these transporters play 
the same roles in synergistic secretion, we stimulated pig tracheal 
glands with 100 nM VIP combined with 50 nM carbachol either 
in Krebs-Ringer buffer or in the presence of bumetanide, HEPES, 
or the combination (n = 2–3, 11–22 glands). As shown in Figure 8, 
interference with transport of either anion inhibited mucus secre-
tion in response to VIP or VIP plus carbachol by 45%–75%, and the 
combination of bumetanide and HEPES inhibited mucus secre-
tion by approximately 90%. A potentially interesting point is that 
bumetanide inhibited the synergistic response more effectively 
(78%) than did HEPES replacement of HCO3– (P < 0.02). This con-
trasts with inhibition of responses to saturating levels of VIP, for-
skolin, or carbachol used individually, which are equally inhibited 
by HEPES or bumetanide (14, 25).
Discussion
The purpose of these experiments was to test the hypothesis that 
airway glands secrete significant amounts of mucus in response to 
low levels of VIP and ACh applied together. We asked this question 
because ACh and VIP are abundant neurotransmitters used by air-
way neurons (reviewed in ref. 23) and because of a new hypothesis 
that routine, “housekeeping” mucus secretion by airway glands is 
produced by low levels of activity in airway intrinsic neurons, with 
such secretion constituting an important component of airway 
mucosal defenses against mundane pathogens (23).
We found that nanomolar concentrations of VIP and carbachol 
acted synergistically to produce airway gland mucus secretion 
in both humans and pigs. Such secretion was CFTR dependent, 
because it was absent in airways from CF subjects and was inhib-
ited in pig airways by CFTRinh-172. The interaction between VIP 
and carbachol appeared to occur at the level of gland cells and not 
neurons, because (a) it was dependent on CFTR; (b) forskolin sub-
stituted for VIP; (c) the K+ channel opener 1-EBIO substituted for 
carbachol; and (d) it was inhibited by the Ca2+-activated K+ channel 
inhibitor clotrimazole. However, we cannot entirely exclude effects 
that might occur if CFTR were also expressed in neurons.
Mechanism of synergy. Models of gland fluid secretion begin with 
the evidence that secretion was driven by electrogenic Cl–, HCO3–, 
Figure 7
Synergistic stimulation of mucus secretion from pig airway glands 
depends upon the recruitment of Ca2+-activated K+ channels. (A) 
The response to 100 nM VIP plus 50 nM carbachol was substantially 
reduced by 25 μM clotrimazole. (B) Clotrimazole did not inhibit the 
response to VIP alone, but prevented the increase observed with car-
bachol combined with VIP. (C) 1-EBIO alone (500 μM) did not stimu-
late mucus secretion, but significantly enhanced secretion produced by 
100 nM VIP. In A–C, each point represents the mucus secretion rate of 
a single gland averaged over the preceding 20-minute period of stimu-
lation. Conditions were separated by 1-minute washes. The connect-
ing lines are visual aids to allow tracking of each gland in the various 
conditions. (D) Summary data for experiments with clotrimazole (Clot; 
left, n = 3, 23 glands) and 1-EBIO (right, n = 3, 26 glands). *P < 0.05.
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and K+ secretion and was augmented by cellular hyperpolarization. 
A minimal model of fluid secretion by gland serous cells is shown 
in Figure 9. This model has much in common with a model devel-
oped for sweat secretion (48, 49). Our data are consistent with the 
following points. (a) Low concentrations of ACh activate K+ chan-
nels but do not activate any apical anion conductances (Figure 9A). 
(b) Low concentrations of VIP can activate CFTR but apparently 
have little effect on basolateral K+ channels (Figure 9B). Therefore, 
little or no fluid secretion occurs for these 2 conditions. (c) When 
combined, the dual activation of basolateral K+ channel and apical 
CFTR supports anion-mediated fluid secretion (Figure 9C). NKCC 
and other basolateral transporters are active in this condition, but 
the exact mechanisms for that activation are unclear. (d) Higher 
levels of ACh alone recruit Ca2+-activated chloride channels and so 
produce fluid secretion (Figure 9D). Higher concentrations of VIP 
alone can recruit basolateral cAMP-dependent K+ channels and also 
support fluid secretion (5). Thus, at higher concentrations of these 
agonists, or higher rates of neural activity, each agonist alone can 
support mucus secretion. In this model, gland mucus secretion in 
response to VIP alone or to VIP in combination with low levels of 
carbachol depends absolutely on CFTR, whereas mucus secretion 
in response to higher levels of carbachol is, at least in part, indepen-
dent of CFTR. Too many uncertainties remain to allow a quantita-
tive model of gland secretion to be formulated and tested.
Differences with prior studies of various glands. Shimura et al. mea-
sured glycoconjugate in a study of VIP-carbachol synergism in iso-
lated cat glands (29). The authors concluded that synergy probably 
resulted from VIP stimulation of muscarinic receptors on neuron 
terminals because they could not duplicate synergy by substituting 
db-cAMP for VIP (29). However, we found here that forskolin did 
substitute for VIP (Figure 4C) and that synergy depended upon 
CFTR and Ca2+-activated K+ channels, supporting a postrecep-
tor process in gland cells as the site of synergy. Sato and Sato (50) 
studied interactions between methacholine and VIP in monkey 
palm sweat glands and observed a marked enhancement of cAMP 
accumulation when methacholine was combined with VIP, but no 
synergistic effect on the sweat secretion rate. In cat salivary glands, 
VIP does not itself stimulate secretion, but greatly increases the 
affinity of agonists to muscarinic receptors (51); this effect was not 
observed by the same investigators in rat cardiac muscles, indicat-
ing tissue specificity for effect (51). These differences indicate that 
large species and end organ differences can exist in responses to 
VIP and interactions between VIP and ACh. It is therefore impor-
tant that we observed VIP/carbachol synergy in airway glands of 
Figure 8
Contribution of Cl– transport (NKCC1) and HCO3– transport to mucus 
secretion produced by 100 nM VIP or 100 nM VIP plus 50 nM carba-
chol. The mucus secretion rate prior to stimulation in these experiments 
was essentially 0 (<0.02 nl/min/gland). VIP-stimulated mucus secretion 
was equally and significantly (P < 0.05) inhibited by the NKCC inhibitor 
bumetanide or by replacement of HCO3– with HEPES, and the com-
bined treatment eliminated greater than 90% of mucus secretion. The 
combined agonists bumetanide and HEPES again caused significant 
inhibition of mucus secretion that was additive, but in this condition 
bumetanide was significantly more inhibitory than was HEPES (P < 0.02). 
For each condition the number of subjects and number of glands (in 
parentheses) is shown.
Figure 9
A minimal gland cell model for synergistic interactions between nano-
molar carbachol and VIP on submucosal gland fluid secretion. (A) Low 
levels of ACh do not produce effective fluid secretion because they 
activate K+ channels (K2) but not apical Cl– channels. (B) Low levels 
of VIP do not produce effective fluid secretion because they activate 
CFTR but not K+ channels. (C) When combined at low levels, ACh (i) 
activates Ca2+-activated K+ channels (K2) to increase the driving force 
through CFTR; it may also increase activity of basolateral transporters. 
VIP opens CFTR (ii), allowing electrogenic, anion-mediated fluid secre-
tion. (D) At higher levels of ACh, apical Ca2+-activated chloride chan-
nels (CaCC) are activated (iii); at higher levels of VIP, cAMP-activated 
K+ channels (K1) are activated (iv). Thus, at higher rates of stimulation 
each pathway alone can produce enough fluid to support mucus secre-
tion. Major unresolved points are the types of gland mucus secretory 
cells that express Ca2+-activated chloride channels (serous, mucous, 
or both) and the relative magnitudes of the apical conductances medi-
ated by each type of channel. The apical K+ channel is based on sin-
gle channel recordings in Calu-3 cells (61) and gland cells (J.V. Wu, 
unpublished observations).
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both humans and pigs. Notably, we have also demonstrated syn-
ergy in WT but not cftr–/– mouse tracheal submucosal glands (our 
unpublished observations).
Functional relevance of low levels of gland mucus secretion. With 50 
nM carbachol plus 50 nM VIP, mucus secretion was about 1 nl/
min/gland (Figure 5). In the trachea, glands are present at a den-
sity of approximately 1 per mm2 (52). If the glands were the only 
source of fluid, and in the absence of other factors, the observed 
mucus secretion rate would produce a 7-μm-deep film of surface 
fluid within about 7 minutes, which is sufficient for mucociliary 
clearance (53). Much of the fluid secreted into the airways is reab-
sorbed, raising interesting questions about the fate of macromo-
lecular components of mucus.
Little information is available on levels of neural input to glands, 
and most studies emphasize vagal control via centrally mediated 
lung defense reflexes. However, evidence is emerging that networks 
of airway intrinsic neurons can mediate mucus secretion in the 
absence of central input (23). For example, transplanted lungs lack 
central neural input and must rely on the intrinsic nervous system 
for basal mucus secretion and to respond to mucosal insults (22); 
mucus clearance continues in transplanted lungs at either a simi-
lar (54) or a reduced rate (55, 56), and glands in tracheae explanted 
into nude mice still secrete lysozyme in the absence of any central 
neural connections; they produce 8.5-fold more lysozyme than is 
found in airways without glands (12). Intact central connections 
provide an additional level of central excitatory vagal tone (24), 
and no neural inhibition of airway intrinsic neurons is thought to 
exist (24). The synergy observed between ACh and VIP, both abun-
dantly expressed in airway intrinsic neurons, may be important 
for basal gland mucus secretion and local responses to mucosal 
irritants (22), but experiments with intact lungs are required to 
address these questions.
Relation to CF. Gland mucus secretion is absolutely CFTR depen-
dent when it is mediated by VIP or forskolin alone (5). In the pres-
ent study, we have shown that it is also CFTR dependent when 
evoked synergistically by VIP and ACh. It may be relevant that 
mice lacking VIP have increased airway inflammation (57). It is 
also interesting that 2 previous studies reported reduced levels 
of VIP nerves around CF sweat glands (58) and VIP binding sites 
in CF airways (59). A generalized deficiency in VIP innervation 
of exocrine organs was once hypothesized to be the basic defect 
in CF, but we now know that any deficiencies must somehow be 
secondary to the loss of CFTR. Secondary changes in VIP innerva-
tion or receptors cannot explain the loss of CF gland responses 
we observed, because responses are also lost to forskolin given 
either alone (5) or as part of a synergy paradigm. Also, isolated 
CF glands imaged with differential interference contrast optics 
were still capable of responding to VIP with exocytosis and cell 
volume changes, although without appreciable bulk mucus flow 
(our unpublished observations). If combinations of ACh and VIP 
are important for low-level mucus secretion by airway glands, CF 
airway glands will secrete less mucus in any conditions that elicit 
such secretion, which would be expected to result in reduced anti-
microbial levels and clearance. In contrast, emergency parasympa-
thetic airway defense reflexes activate glands via strong cholinergic 
stimulation, and this pathway is, at least in part, spared in CF air-
ways (5, 15, 22, 26, 37–40). Treatments that evoke the vagal reflexes 
(60) may be beneficial for some people with CF.
Methods
Human airway preparations. Human tracheal and bronchial tissues were 
obtained following lung transplants and were used within 24 hours. These 
studies were approved by the Institutional Review Boards of Stanford Uni-
versity, and tissue was only used from patients who had provided written 
informed consent. Data were obtained from 9 donor tracheae, 7 bronchi 
from patients with CF, and 7 bronchi from patients who were transplanted 
for diseases other than CF. Three lungs were from patients who had chron-
ic obstructive pulmonary disease, and the remaining 4 non-CF tissues were 
from patients with α1-antitrypsin deficiency, interstitial pneumonitis type II 
autoimmune hepatitis, transposition of greater vessels, and idiopathic pul-
monary fibrosis-usual interstitial pneumonia. Results for these 7 subjects 
did not differ from one another or from the donor trachea, so results from 
all 16 control subjects were combined for comparison with CF subjects. 
Subject characteristics are given in Table 1.
Porcine preparations. Pig tracheae were obtained from fresh carcasses of juve-
nile Yorkshire pigs of either sex weighing 35–50 kg following acute experi-
ments carried out for other purposes. No pigs were sacrificed specifically 
for the present experiments, nevertheless, the experiments were approved 
by Stanford University’s Institutional Animal Care and Use Committee 
(IACUC). A total of 34 pig tracheae were used for these experiments.
Human and pig tissues were treated the same after harvesting. They were 
transported to the laboratory in cold Physiosol solution (Abbott Laborato-
ries) and were then transferred to ice-cold Krebs-Ringer bicarbonate buffer 
bubbled with 95% O2 and 5% CO2, where they were maintained until use. 
The Krebs-Ringer buffer composition was 115 mM NaCl, 2.4 mM K2HPO4, 
0.4 mM KH2PO4, 25 mM NaHCO3, 1.2 mM MgCl2, 1.2 mM CaCl2, 10 mM 
glucose, and 1.0 μM indomethacin. The pH was 7.4 and osmolarity was 
adjusted to approximately 290 milliosmoles. A piece of ventral trachea or 
bronchus of about 0.5 cm2 was pinned mucosal side up, and the mucosa 
with underlying glands was dissected from the cartilage and mounted in a 
35-mm-diameter plastic Petri dish lined with Sylgard (Dow Corning Corp.), 
with the serosa in the bath (~1 ml volume) and the mucosa in air. The tis-
sue surface was cleaned and blotted dry with cotton swabs and further 
dried with a stream of gas, after which 20–30 μl of water-saturated mineral 
oil was placed on the surface. The tissue was warmed to 37°C at a rate of 
about 1.5°C/min and continuously superfused with warmed, humidified 
95% O2 and 5% CO2. Pharmacological agents were diluted to final concen-
trations with warmed, gassed bath solution and were added to the serosal 
side by complete bath replacement.
Optical measurements. Bubbles of mucus within the oil layer were visual-
ized by oblique illumination and digital images were captured with the 
macro lens of a Nikon digital camera. Each image contained an internal 
reference grid to compensate for any minor adjustments in magnifica-
tion made during the experiment. Stored images were analyzed either by 
direct measurement or with NIH ImageJ software (http://rsb.info.nih.
gov/ij/). Mucus volumes were determined from the size of the spheri-
cal bubbles; bubbles that were not approximately spherical were omit-
ted from mucus secretion rate analyses. Details of these methods are 
given in ref. 25.
Table 1
Subject characteristics
	 Donor	 Other	disease	 CF
n 9A 7 7
Male (no. [%]) 4 (50) 3 (43) 3 (43)
Age (mean ± SD) 38 ± 13 57 ± 9 27 ± 16
AAge and sex characteristics were not retrieved for 1 donor trachea.
research article
3126	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 117   Number 10   October 2007
Reagents. Compounds (Sigma-Aldrich) were made fresh or maintained at 
–20°C. Stock solutions of carbachol, VIP, atropine, and bumetanide were 
dissolved in distilled water; indomethacin was dissolved in ethanol; and 
forskolin, 1-EBIO, CFTRinh-172, niflumic acid, and clotrimazole were dis-
solved in DMSO. All were diluted 1:1,000 with bath solution (except indo-
methacin, diluted 1:10,000) immediately before use at the concentrations 
indicated. The highest DMSO concentration in our experiments was 0.2% 
and the highest ethanol concentration was 0.01%; we tested 0.5% DMSO as 
vehicle alone and found no effect.
Statistics. Data are mean ± SEM. Unless otherwise indicated, means of dif-
ferent treatment groups were compared with Student’s t test for unpaired 
data. A P value less than 0.05 was considered significant. Curves were fit 
with Origin software (OriginLab Corp.) using a sigmoid function.
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